A monoclonal blocking EIA for herpes simplex virus type 2 antibody: validation for seroepidemiological studies in Africa.
A competitive type-specific enzyme-linked immunosorbent assay (ELISA) for herpes simplex virus type 2 (HSV-2) antibody was developed using an infected cell antigen and a monoclonal antibody to glycoprotein G-2. This assay has been validated for use for epidemiological studies using a large panel of sera collected in rural Uganda and a panel of 143 sera characterised previously by Western blotting, the 'gold standard' for HSV type-specific serology. This evaluation was found to have a sensitivity of 96% and a specificity of 91% in comparison with Western blot on 143 sera from clinic patients. The ELISA had a sensitivity of 93% and a specificity of 91% in comparison with Western blot on 495 sera collected in Uganda. The assay showed good reproducibility and a low percentage of sera gave equivocal results, indicating its suitability for epidemiological studies.
Gopal
R
R
Enteric and Respiratory Virus Laboratory Virus, Central Public Health Laboratory, London, UK.
Gibbs
T
T
Slomka
M J
MJ
Whitworth
J
J
Carpenter
L M
LM
Vyse
A
A
Brown
D W
DW
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006561:Herpes Simplex / Q000453:epidemiology* / Q000821:virology; D018258:Herpesvirus 2, Human / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012698:Serologic Tests; D014454:Uganda / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral